Argininosuccinic Aciduria Treatment Market Trends Analysis
Argininosuccinic aciduria or argininosuccinate lyase deficiency is one of the inherited disorders belonging to urea cycle disorders, which cause ammonia to accumulate in the blood. Argininosuccinic Aciduria is the second most common UCD.
As per the DelveInsight estimates, in 2017, the USA accounted for the highest Incident population of Argininosuccinic Aciduria, holding up-to 208 cases. While, among the EU5 countries (the United Kingdom, Germany, Italy, France and Spain), Germany had the highest incident population of ASA with 35 cases, followed by France and the United Kingdom. While, Spain accounted for the lowest incident cases of Argininosuccinic Aciduria among the EU5 countries, i.e., 21 in 2017.
The Argininosuccinic Aciduria treatment market presently holds some potential pharma companies developing new therapies, some of the key players in includes Acer Therapeutics, Evox Therapeutics, Promethera Biosciences, PhaseRx and many others.
For more details on Argininosuccinic Aciduria Treatment Market Trends Analysis, visit: https://www.delveinsight.com/blog/argininosuccinic-aciduria-treatment-market/